KBC Group
VRDN icon

KBC Group’s Viridian Therapeutics VRDN Stock Holding History

KBC Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76K Buy
4,120
+2,383
+137% +$38.4K ﹤0.01% 1554
2026
Q1 		$34K Buy
+1,737
New +$51.6K ﹤0.01% 1773

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

KBC Group's VRDN Position: Q2 2026 in Review

KBC Group increased its Viridian Therapeutics (VRDN) stake by 137% in Q2 2026, buying an estimated $38.4K and bringing the position to 4,120 shares worth $76K. The position accounts for ﹤0.01% of the portfolio, ranked #1554.

KBC Group first reported a position in VRDN in Q1 2026 and has held it in 2 quarters since. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • KBC Group held 4,120 shares of Viridian Therapeutics worth $76K as of Q2 2026.
  • KBC Group bought 2,383 Viridian Therapeutics shares in Q2 2026, an estimated $38.4K.
  • Viridian Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1554 holding.
  • KBC Group first reported a position in Viridian Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.